The insider sales are small relative to market cap and likely reflect routine portfolio diversification after a 49% stock surge post-earnings. Monitor for any additional insider selling at higher volumes (>0.5% of market cap) which would be more concerning. The fundamental story remains intact with rapid path to profitability and raised guidance.
Drug in focus
INSM drug pipeline →BRINSUPRI
▲ Bullish Named in this insider cluster- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially launched in the US (August 2025), EU (November 2025), and Japan (August 2026)
- Next catalyst
- None dated
What to watchBRINSUPRI is already a commercial success with a blockbuster launch trajectory, but the stock has pulled back ~40% from its 52-week high of $212.75. With no imminent binary catalyst (the drug is already approved globally), the investment thesis hinges on continued commercial execution and pipeline progress from Insmed's other assets (TPIP, ARIKAYCE). Watch quarterly prescription trends and any label-expansion updates for brensocatib.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 20 $125.08entry
- T+1 · 3mo ago +0.55%α +0.14% · $125.77
- T+5 · 3mo ago −2.95%α −4.06% · $121.39
- T+20 · 2mo ago −4.06%α −4.19% · $120.00
- T+60 · 4d ago −5.60%α −4.77% · $118.07
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Insmed insiders sold a total of $32.6M in stock over the past week, including COO Roger Adsett's $31.96M sale and Director Melvin Sharoky's $638K sale. This cluster follows a blockbuster Q2 earnings beat (revenue $425.5M vs $393.4M consensus) and a raised full-year BRINSUPRI guidance to $1.25B-$1.4B. While the sales are large in absolute terms, they represent only ~0.12% of the $28.1B market cap, and the COO's sale may be a routine 10b5-1 plan transaction following a massive stock appreciation post-earnings. The cluster does not negate the strong fundamental momentum.
Key Financial Metrics
Key Facts
- COO Roger Adsett sold 239,800 shares for $31.96M on 2026-08-10 at $133.27
- Director Melvin Sharoky sold 5,000 shares for $637,650 on 2026-08-17 at $127.53
- Total insider sales of $32.6M represent ~0.12% of INSM's $28.1B market cap
- Sales follow Q2 2026 earnings beat: revenue $425.5M vs consensus $393.4M, BRINSUPRI sales surged 49% QoQ to $309.2M
- Full-year BRINSUPRI guidance raised to $1.25B-$1.4B from 'at least $1B'
Financial Impact
Insider sales of $32.6M total, ~0.12% of market cap, below materiality threshold
Risk Factors
- COO's large sale could signal peak sentiment if it accelerates
- Stock has appreciated significantly post-earnings, creating natural selling pressure from insiders
- Any future insider sales cluster above 0.5% of market cap would warrant bearish reassessment
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-INSM-1787196620318 |
Track record
24 reports on INSM
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +31.86% at T+60 after the Mar 30, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $110.00 Now $121.16 +10.15% settles Dec 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $110.00 Now $121.16 +10.15% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $111.59 Now $121.16 +8.58% settles Nov 27
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $94.04 Now $121.16 +28.84% settles Nov 18
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $95.67 Now $121.16 +26.64% settles Nov 17
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $103.83 to $112.58 Now $121.16 +16.69% ▲ +8.43% +10.89% vs SPY
- Aug 19, 202612w ago Insider Cluster Neutral 4/10 Viewing Entry $125.08 to $120.00 Now $121.16 −3.13% ▼ −4.06% −4.19% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $126.33 to $129.41 Now $121.16 −4.09% ▲ +2.44% +4.19% vs SPY
- Aug 6, 202614w ago 8-K Bullish 8/10 Entry $132.55 to $126.68 Now $121.16 −8.59% ▼ −4.43% −5.03% vs SPY
- Jul 24, 202616w ago Institutional Cluster Neutral 4/10 Entry $106.92 to $125.77 Now $121.16 +13.32% ▲ +17.63% +14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers